NEWS

Pharmaceutical company from germany (BioNTech) has started testing a potential vaccine for the novel coronavirus on Humans.

BioNTech, working with the Pfizer which is US based Pharmaceutical company, said on Wednesday that 12 participants of a clinical trial in Germany received doses of the vaccine candidate BNT162 since April 23.

they said in a statement that in the next step will be to increase the dose of BNT162 in a trial involving about 200 participants aged 18 to 55.

they are expecting get regulatory approval from United State soon.

While a safe, efficient vaccine is still more than one year away, researchers are hurring to repurpose existing drugs and non-drug therapies as well as testing guaranteed experimental drugs that were already in clinical trials.

Even moderately efficient therapies or combinations could dramatically reduce the crushing demand on hospitals and intensive care units, changing the nature of the risk the new pathogen represents to populations and healthcare systems.

New drugs, together with new diagnostics, antibody tests, patient- and contact-tracing technologies, disease surveillance and other early-warning tools, mean the anticipated next "wave" of the global pandemic does not have to be nearly as bad as the first.

As many as 100 potential corona infected candidate vaccines are now under development by biotech and research teams around the world, and at least five of these are in preliminary testing in people in what are known as Phase 1 clinical trials.

Scientists in the United Kingdom began clinical trials of a potential COVID-19 vaccine on April 23 as other vaccine developers across Europe stepped up work on experimental shots.

The team at the UK's Oxford University dosed the first volunteers in a trial of their vaccine - called "ChAdOx1 nCoV-19" - while Italy's ReiThera, Germany's Leukocare and Belgium's Univercells said they were working together on another potential shot and aimed to start trials in a few months.

The UK's GSK and France's Sanofi have announced a similar agreement to develop a COVID-19 vaccine, with trials starting in the second half of the year.